Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Phosphorylation-induced structural remodeling of band 3 as a driver of metabolic dysfunction in sickle cell disease

Amy Argabright, Shaun Bevers, Aaron Issaian et al. Nov 03, 2025 pp. 2928-2928 10.1182/blood-2025-2928

Abstract Red blood cells (RBCs), devoid of nuclei and organelles, rely on post-translational modifications and dynamic protein–protein inter...

T cell fitness and tumor specificity predict immunotherapy response in multiple myeloma

Niklas Kehl, Simon Steiger, Tim Wagner et al. Nov 03, 2025 pp. 1029-1029 10.1182/blood-2025-1029

Abstract T cells are increasingly recognized as central effectors in the therapeutic response across a wide spectrum of treatments for multi...

VIP pathway inhibition alters microbial metabolism to balance graft-versus-leukemia and gvhd

Kayla Robinson, Shayna Jankowski, Jian-Ming Li et al. Nov 03, 2025 pp. 6034-6034 10.1182/blood-2025-6034

Abstract Introduction: Emerging evidence highlights the gut microbiome as a critical player in gastrointestinal acute graft-versus-host dise...

Efficacy of acute normovolemic hemodilution in adult cardiac surgery in reducing the need for allogenic red cell transfusion: A systematic review and updated meta-analysis of randomized controlled trials.

Tejaswini Mariappan, Noorul Hidhaya S, Gurunathan Srinivasan et al. Nov 03, 2025 pp. 1370-1370 10.1182/blood-2025-1370

Abstract Introduction: Allogeneic red blood cell transfusions during cardiac surgery increase risks of immunologic reactions, infections, an...

Phase 1 study of revumenib in combination with intensive chemotherapy (IC) in patients (Pts) with newly diagnosed (ND) Acute Myeloid Leukemia (AML) harboring genetic alterations in KMT2A, NPM1, or NUP98: SNDX-5613-0708

Ibrahim Aldoss, Carl Shultz, Bradley Hunter et al. Nov 03, 2025 pp. 3425-3425 10.1182/blood-2025-3425

Abstract Introduction: Acute leukemias (AL) harboring a KMT2A or NUP98 rearrangement (KMT2Ar or NUP98r) confer unfavorable prognosis, and whi...

A novel prognostic model for predicting mortality in adults with sickle cell disease and severe sinusoidal obstruction syndrome

Jessica Mcclain, Parth Thaker, Marwah Farooqui et al. Nov 03, 2025 pp. 532-532 10.1182/blood-2025-532

Abstract Background: Liver involvement in sickle cell disease (SCD) is often underdiagnosed, with hepatic complications...

Momelotinib-mediated transcriptional reprogramming induces synthetic lethal interaction with calcineurin-NFAT signaling

Sekhu Ansari, Meenu Kesarwani, Zachary Kincaid et al. Nov 03, 2025 pp. 756-756 10.1182/blood-2025-756

Abstract Despite notable advances in the development of targeted therapies for acute myeloid leukemia (AML), the emergence of treatment resi...

Novel approaches to identify cellular vulnerabilities in TET2-dependent MDS

Valeria Visconte, Arda Durmaz, Carmelo Gurnari et al. Nov 03, 2025 pp. 3838-3838 10.1182/blood-2025-3838

Abstract MDS and related disorders manifest a tremendous diversity of molecular patterns originating from the founder lesions and depending...

A prognostic model integrating disease‑ and patient‑oriented factors identifies poor‑outcome patients with low‑risk MDS: A multicenter real‑world cohort study (KOTOSG)

Takahisa Nakamura, Haruya Okamoto, Takahiro Fujino et al. Nov 03, 2025 pp. 5633-5633 10.1182/blood-2025-5633

Abstract Background Low-risk myelodysplastic syndromes (LR-MDS) are generally associated with a lower risk of progressing to leukemia and te...

Real-world analysis of ravulizumab safety and effectiveness in advanced age patients with paroxysmal nocturnal hemoglobinuria: Insights from the international PNH registry

Shreyans Gandhi, Ami Patel, Alix Augustin-Wright et al. Nov 03, 2025 pp. 6238-6238 10.1182/blood-2025-6238

Abstract Background: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by uncontrolled terminal complement ac...

Inhibitor of DNA binding 2 (ID2) is epigenetically regulated during lymphomagenesis and constitutes a novel therapeutic target in mature T-cell lymphoma

Anouchka Laurent, Hannah I. Miller, Ryan D. Najac et al. Nov 03, 2025 pp. 54-54 10.1182/blood-2025-54

Abstract Mature T-cell lymphomas (TCL) are a heterogeneous group of non-Hodgkin lymphomas arising from the malignant transformation of post-...

SOUNDTRACK-F1: A phase 3, randomized, open-label study of surovatamig (AZD0486) plus rituximab versus chemotherapy plus rituximab in patients with previously untreated follicular lymphoma

Chan Cheah, Monique Menzies Wojtowicz, Dok Hyun Yoon et al. Nov 03, 2025 pp. 3614-3614 10.1182/blood-2025-3614

Abstract Background and Significance: Follicular lymphoma (FL) is the most common indolent lymphoma and advanced-stage disease is considered...

Machine learning ensemble models for genetic-based classification of myeloproliferative and myelodysplastic/myeloproliferative neoplasms: Comparing a multinomial vs binomial approach

Jade Zezzi Martins do Nascimento, Amanda Inácio Dias Ennes, Mariana Lorenzi Savioli et al. Nov 03, 2025 pp. 7868-7868 10.1182/blood-2025-7868

Abstract Background Myeloid malignancies such as myeloproliferative neoplasms (MPNs) and myelodysplastic/myeloproliferative neoplasms (MDS/M...

Significance of CD229 expression assessment for detection of minimal residual disease in patients with multiple myeloma.

Darya Kisilichina, Iuliia Oleinik, Victoria Skurikhina et al. Nov 03, 2025 pp. 3991-3991 10.1182/blood-2025-3991

Abstract Introduction Multiparameter flow cytometry (MFC) is one of the most reliable methods for monitoring minimal res...

A case series of pediatric patients with congenital thrombotic thrombocytopenia purpura (cTTP) treated with recombinant ADAMTS13

Erin Christensen, Katie Lawrence, Beth Warren et al. Nov 03, 2025 pp. 3112-3112 10.1182/blood-2025-3112

Abstract Background: Congenital thrombotic thrombocytopenic purpura (cTTP), also known as Upshaw-Schulman Syndrome, is an ultra-rare thrombot...

Second autologous transplantation remains a valid consolidation option in patients with relapsed multiple myeloma: A report from the Latin American bone marrow transplantation group

Martín Milanesio, Byron Figueroa, Sebastián Galeano et al. Nov 03, 2025 pp. 5839-5839 10.1182/blood-2025-5839

Abstract INTRODUCTION With the advent of novel therapeutic agents, the management of relapsed multiple myeloma (MM) has shifted markedly, an...

Real-world study on thrombopoietin receptor agonists combined with rituximab in the treatment of Relapsed/Refractory primary immune thrombocytopenia

Hong Tian, Xuewen Song, Ruinan Lu et al. Nov 03, 2025 pp. 3048-3048 10.1182/blood-2025-3048

Abstract Background Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder, but the management of relapsed/refractory cases remain...

Detection of KMT2A fusion transcripts after induction chemotherapy is strongly predictive of outcome in KMT2A rearranged AML: Results of an international collaborative study

Jad Othman, Hsin-An Hou, Nicola Potter et al. Nov 03, 2025 pp. 346-346 10.1182/blood-2025-346

Abstract KMT2A rearrangements (KMT2Ar) occur in ~5% of adult AML, making adequately powered studies of prognostic factors challenging. We an...

CD19 antigen: From tumor target to safety switch able to improve the safety profile of CAR T cell therapy

Simona Manni, Laura Iaffaldano, Maria Cecilia Quadraccia et al. Nov 03, 2025 pp. 2541-2541 10.1182/blood-2025-2541

Abstract Background Chimeric antigen receptor (CAR) T cell therapy is an innovative immunotherapeutic approach that has...

MGA loss promotes mitochondrial structure changes and redox adaptation in richter's transformation

Prajish Iyer, Girish Venkataraman, Joo Song et al. Nov 03, 2025 pp. 5655-5655 10.1182/blood-2025-5655

Abstract Richter's transformation, a highly aggressive and therapy-refractory progression of chronic lymphocytic leukemia (CLL), is characte...

Use of G-CSF in AML patients with febrile neutropenia: Friend or foe?

Zaid Zahid, Mohammad Salameh, Jamil Nazzal et al. Nov 03, 2025 pp. 3414-3414 10.1182/blood-2025-3414

Abstract Background Febrile neutropenia (FN) is a common and potentially life-threatening complication in patients with acute myeloid leukemi...

Regulatory long noncoding RNA of T cells (ReLoT/LINC00402) impairs Rorγt+ allogeneic T cells

Van Anh Do-Thi, Emma Bratch, Jathniel Hernandez et al. Nov 03, 2025 pp. 161-161 10.1182/blood-2025-161

Abstract Long noncoding RNAs (lncRNA) are versatile cell- and context-specific regulators of immune cell responses. As such, they may be ide...

Outcomes of elderly (≥ 70) Acute Myeloid Leukemia (AML) patients receiving continued hypomethylating agent/venetoclax (HMA/VEN) versus allogeneic hematopoietic cell transplantation (HCT)

Onyee Chan, Reshma Ramlal, syeda mahrukh naqvi et al. Nov 03, 2025 pp. 4300-4300 10.1182/blood-2025-4300

Abstract Introduction: HMA/VEN has transformed therapy for elderly patients with AML by improving complete remission (CR) rates, survival, a...

Quality of life and functional improvements with efanesoctocog alfa in patients with moderate-to-severe Hemophilia A: A real-world survey

Maissaa Janbain, Miguel Escobar, Manuel Carcao et al. Nov 03, 2025 pp. 4846-4846 10.1182/blood-2025-4846

Abstract Background: Hemophilia A (HA) is a rare X-linked bleeding disorder characterized by deficiency or dysfunction of clotting factor VI...

Defining evolutionary trajectories in myelodysplastic syndromes and integrating them into prognostic models to improve risk stratification: The progevo machine learning approach

Ivan Civettini, Federica Malighetti, Matteo Villa et al. Nov 03, 2025 pp. 3847-3847 10.1182/blood-2025-3847

Abstract Background Myelodysplastic Syndromes (MDS) are clonal hematopoietic stem cell disorders that evolve following a multi-step process....

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page